2/5 Late treatment study
et al., Revue des Maladies Respiratoires, doi:10.1016/j.rmr.2021.02.001 (Peer Reviewed)
Factors associated with the occurrence of acute respiratory distress and death in patients with COVID-19 in Burkina Faso
Factors associated with the occurrence of acute respiratory distress and death in patients with COVID-19 in Burkina Faso
Retrospective 456 patients in Burkina Faso showing lower risk of ARDS (p=0.001) and mortality (p=0.38) with HCQ.
Ouedraogo et al., 2/5/2021, retrospective, Burkina Faso, Africa, peer-reviewed, 14 authors.
risk of death, 33.0% lower, RR 0.67, p = 0.38, treatment 397, control 59, multivariate.
risk of ARDS, 68.0% lower, RR 0.32, p = 0.001, treatment 397, control 59, multivariate, RR approximated with OR.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical signficance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.